Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group
| Autor: | Hammond D, J. Grosfeld, Robert E. Hittle, Samuel McCreadie, Sanford L. Leikin, J Z Finklestein, H N Sather, John M. Weiner, Evans Ae, I. Bernstein, Klemperer M |
|---|---|
| Rok vydání: | 1979 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Vincristine Cyclophosphamide Adolescent medicine.medical_treatment Antineoplastic Agents Neuroblastoma Pharmacotherapy Actuarial Analysis Internal medicine medicine Humans Neoplasm Metastasis Child Imidazole carboxamide Chemotherapy business.industry Imidazoles Cancer Infant Multimodal therapy medicine.disease Surgery Doxorubicin Child Preschool Pediatrics Perinatology and Child Health Drug Therapy Combination business medicine.drug |
| Zdroj: | Medical and pediatric oncology. 6(2) |
| ISSN: | 0098-1532 |
| Popis: | During the past 10-15 years there has not been a significant improvement in the overall survival of children with metastatic neuroblastoma. From 1971 through 1975, 104 eligible patients were entered on two clinical studies for newly diagnosed cases of stage IV neuroblastoma by the Childrens Cancer Study Group (CCSG). Patient data from both studies were evaluated for activity of cyclophosphamide, imidazole carboxamide, and vincristine and of these same agents plus adriamycin. Response was evaluated by serial measurements of tumor size. Eighty-four patients experienced a complete or partial response. The life-table estimate of median survival on both studies was 11–12 months for all patients and 13-18 months for responders, unchanged from the results of previous CCSG studies. Long-term survival, however, for patients on these studies demonstrates a significant increase compared with results reported from the three previous CCSG studies. Children less than 1 year or greater than 6 years of age at diagnosis showed a significantly improved survival pattern over the intermediate age group. It is suggested that there is a need to consider the induction response pattern and age at diagnosis when planning a maintenance program so that nonresponders can be identified early and considered for treatment with new agents or aggressive multimodal therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text